Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer
Immunotherapy, which stimulates the body’s immune system, has received a considerable amount of press in recent years because of its powerful benefits. Cancer immunotherapy has shown long-term results in patients with advanced disease that are not seen with traditional chemotherapy. Immune checkpoin...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/27/12/3798 |
| _version_ | 1797484028424617984 |
|---|---|
| author | Md. Mominur Rahman Tapan Behl Md. Rezaul Islam Md. Noor Alam Md. Mohaimenul Islam Ali Albarrati Mohammed Albratty Abdulkarim M. Meraya Simona Gabriela Bungau |
| author_facet | Md. Mominur Rahman Tapan Behl Md. Rezaul Islam Md. Noor Alam Md. Mohaimenul Islam Ali Albarrati Mohammed Albratty Abdulkarim M. Meraya Simona Gabriela Bungau |
| author_sort | Md. Mominur Rahman |
| collection | DOAJ |
| description | Immunotherapy, which stimulates the body’s immune system, has received a considerable amount of press in recent years because of its powerful benefits. Cancer immunotherapy has shown long-term results in patients with advanced disease that are not seen with traditional chemotherapy. Immune checkpoint inhibitors, cytokines like interleukin 2 (IL-2) and interferon-alpha (IFN), and the cancer vaccine sipuleucel-T have all been licensed and approved by the FDA for the treatment of various cancers. These immunotherapy treatments boost anticancer responses by stimulating the immune system. As a result, they have the potential to cause serious, even fatal, inflammatory and immune-related side effects in one or more organs. Immune checkpoint inhibitors (ICPIs) and chimeric antigen receptor (CAR) T-cell therapy are two immunotherapy treatments that are increasingly being used to treat cancer. Following their widespread usage in the clinic, a wave of immune-related adverse events (irAEs) impacting virtually every system has raised concerns about their unpredictability and randomness. Despite the fact that the majority of adverse effects are minimal and should be addressed with prudence, the risk of life-threatening complications exists. Although most adverse events are small and should be treated with caution, the risk of life-threatening toxicities should not be underestimated, especially given the subtle and unusual indications that make early detection even more difficult. Treatment for these issues is difficult and necessitates a multidisciplinary approach involving not only oncologists but also other internal medicine doctors to guarantee quick diagnosis and treatment. This study’s purpose is to give a fundamental overview of immunotherapy and cancer-related side effect management strategies. |
| first_indexed | 2024-03-09T22:55:36Z |
| format | Article |
| id | doaj.art-df938fd1350343c68d0db4c13bfd8f21 |
| institution | Directory Open Access Journal |
| issn | 1420-3049 |
| language | English |
| last_indexed | 2024-03-09T22:55:36Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Molecules |
| spelling | doaj.art-df938fd1350343c68d0db4c13bfd8f212023-11-23T18:11:27ZengMDPI AGMolecules1420-30492022-06-012712379810.3390/molecules27123798Emerging Management Approach for the Adverse Events of Immunotherapy of CancerMd. Mominur Rahman0Tapan Behl1Md. Rezaul Islam2Md. Noor Alam3Md. Mohaimenul Islam4Ali Albarrati5Mohammed Albratty6Abdulkarim M. Meraya7Simona Gabriela Bungau8Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, Dhaka 1207, BangladeshChitkara College of Pharmacy, Chitkara University, Rajpura 140401, IndiaDepartment of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, Dhaka 1207, BangladeshDepartment of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, Dhaka 1207, BangladeshDepartment of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, Dhaka 1207, BangladeshRehabilitation Health Sciences, College of Applied Medical Sciences, King Saud University, Riyadh 12372, Saudi ArabiaDepartment of Pharmaceutical Chemsitry, College of Pharmacy, Jazan University, Jazan 45142, Saudi ArabiaPractice Research Unit, Department of Clinical Pharmacy, College of Pharmacy, Jazan University, Jazan 45124, Saudi ArabiaDepartment of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, RomaniaImmunotherapy, which stimulates the body’s immune system, has received a considerable amount of press in recent years because of its powerful benefits. Cancer immunotherapy has shown long-term results in patients with advanced disease that are not seen with traditional chemotherapy. Immune checkpoint inhibitors, cytokines like interleukin 2 (IL-2) and interferon-alpha (IFN), and the cancer vaccine sipuleucel-T have all been licensed and approved by the FDA for the treatment of various cancers. These immunotherapy treatments boost anticancer responses by stimulating the immune system. As a result, they have the potential to cause serious, even fatal, inflammatory and immune-related side effects in one or more organs. Immune checkpoint inhibitors (ICPIs) and chimeric antigen receptor (CAR) T-cell therapy are two immunotherapy treatments that are increasingly being used to treat cancer. Following their widespread usage in the clinic, a wave of immune-related adverse events (irAEs) impacting virtually every system has raised concerns about their unpredictability and randomness. Despite the fact that the majority of adverse effects are minimal and should be addressed with prudence, the risk of life-threatening complications exists. Although most adverse events are small and should be treated with caution, the risk of life-threatening toxicities should not be underestimated, especially given the subtle and unusual indications that make early detection even more difficult. Treatment for these issues is difficult and necessitates a multidisciplinary approach involving not only oncologists but also other internal medicine doctors to guarantee quick diagnosis and treatment. This study’s purpose is to give a fundamental overview of immunotherapy and cancer-related side effect management strategies.https://www.mdpi.com/1420-3049/27/12/3798immunotherapycancerchemotherapyimmune checkpoint inhibitorscytokinesinterferon-alpha |
| spellingShingle | Md. Mominur Rahman Tapan Behl Md. Rezaul Islam Md. Noor Alam Md. Mohaimenul Islam Ali Albarrati Mohammed Albratty Abdulkarim M. Meraya Simona Gabriela Bungau Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer Molecules immunotherapy cancer chemotherapy immune checkpoint inhibitors cytokines interferon-alpha |
| title | Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer |
| title_full | Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer |
| title_fullStr | Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer |
| title_full_unstemmed | Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer |
| title_short | Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer |
| title_sort | emerging management approach for the adverse events of immunotherapy of cancer |
| topic | immunotherapy cancer chemotherapy immune checkpoint inhibitors cytokines interferon-alpha |
| url | https://www.mdpi.com/1420-3049/27/12/3798 |
| work_keys_str_mv | AT mdmominurrahman emergingmanagementapproachfortheadverseeventsofimmunotherapyofcancer AT tapanbehl emergingmanagementapproachfortheadverseeventsofimmunotherapyofcancer AT mdrezaulislam emergingmanagementapproachfortheadverseeventsofimmunotherapyofcancer AT mdnooralam emergingmanagementapproachfortheadverseeventsofimmunotherapyofcancer AT mdmohaimenulislam emergingmanagementapproachfortheadverseeventsofimmunotherapyofcancer AT alialbarrati emergingmanagementapproachfortheadverseeventsofimmunotherapyofcancer AT mohammedalbratty emergingmanagementapproachfortheadverseeventsofimmunotherapyofcancer AT abdulkarimmmeraya emergingmanagementapproachfortheadverseeventsofimmunotherapyofcancer AT simonagabrielabungau emergingmanagementapproachfortheadverseeventsofimmunotherapyofcancer |